DUBLIN--(BUSINESS WIRE)--The "Depression Treatment Market" report has been added to ResearchAndMarkets.com's offering.
A recent market study published on the depression treatment market offers a global industry analysis for 2012-2021 and an opportunity assessment for 2022-2032. The report consists of a comprehensive assessment of the most important market dynamics.
On conducting thorough research on the historical as well as current growth parameters of the depression treatment market, growth prospects of the market are obtained with maximum precision.
The report features unique and salient factors that may make a huge impact on the development of the depression treatment market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in this market in the coming years.
The report provides detailed information about the current and future growth prospects of the depression treatment market in the most comprehensive way for a better understanding of readers.
Companies Mentioned
- Viatris (Mylan Pharmaceuticals Inc.)
- Sunovian Pharmaceuticals
- AbbVie Inc. (Allergan Inc.)
- Jubilant Generics Limited
- Sanis Health Inc.
- Abbott Laboratories
- Aurobindo Pharma
- Torrent Pharmaceuticals
- Teva Pharmaceuticals
- Sun Pharmaceuticals
- (Apotex Holdings Inc.) Apotex Corporation
- Alembic Pharmaceuticals Limited
- Pfizer Inc.
- Cardinal Health
- Hikma Pharmaceuticals
- Zydus Lifesciences (Cadila)
- Cipla Ltd
- Dr. Reddy's Laboratories
- Merck & Co.
- Eli Lily & Co
- GlaxoSmithKline
- Takeda Pharmaceuticals
- BrainsWay Ltd.
- Nexstim Plc
- Magstim Ltd.
- Neuronetics Inc.
- Salience TMS Neuro Solutions
- MagVenture
- MAG & More GmbH
- Neurosoft Ltd.
Key Segments of the Depression treatment Market
This study on the depression treatment market offers information divided into four important segments - products, disease, distribution channel and region.
This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
By Products
- Drugs
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Citalopram
- Escitalopram
- Fluoxetine
- Fluvoxamine
- Paroxetine
- Sertraline
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Desvenlafaxine succinate
- Duloxetine
- Levomilnacipran
- Venlafaxine
- Bupropion
- Mirtazapine
- Monoamine oxidase inhibitors (MAOIs)
- Phenelzine
- Tranylcypromine
- Antipsychotics
- Lithium carbonate
- Aripiprazole
- Brexipiprazole
- Quetiapine
- Trazodone
- Others
- TMS Devices
- rTMS Devices
- dTMS Devices
By Disease
- Major Depression
- Persistent Depressive Disorder
- Bipolar Disorder
- Seasonal Affective Disorder (SAD)
- Postpartum Depression
- Premenstrual Dysphoric Disorder (PDD)
- Situational Depression
- Atypical Depression
- Treatment-Resistant Depression
By Distribution Channel
- Hospitals
- Retail Pharmacies
- Drug Stores
- e-commerce
- Specialty Clinics
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa (MEA)
For more information about this report visit https://www.researchandmarkets.com/r/2h2zat
